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Abstract The circulatory system is walled off by differ-
ent cell types, including vascular mural cells and
podocytes. The interaction and interplay between
endothelial cells (ECs) and mural cells, such as vascular
smooth muscle cells or pericytes, play a pivotal role in
vascular biology. Endoglin is an RGD-containing counter-
receptor for b1 integrins and is highly expressed by ECs
during angiogenesis. We find that the adhesion between
vascular ECs and mural cells is enhanced by integrin
activators and inhibited upon suppression of membrane
endoglin or b1-integrin, as well as by addition of soluble
endoglin (SolEng), anti-integrin a5b1 antibody or an RGD
peptide. Analysis of different endoglin mutants, allowed
the mapping of the endoglin RGD motif as involved in the
adhesion process. In Eng?/- mice, a model for hereditary
hemorrhagic telangectasia type 1, endoglin haploinsuffi-
ciency induces a pericyte-dependent increase in vascular
permeability. Also, transgenic mice overexpressing
SolEng, an animal model for preeclampsia, show podocy-
turia, suggesting that SolEng is responsible for podocytes
detachment from glomerular capillaries. These results
suggest a critical role for endoglin in integrin-mediated
adhesion of mural cells and provide a better understanding
on the mechanisms of vessel maturation in normal physi-
ology as well as in pathologies such as preeclampsia or
hereditary hemorrhagic telangiectasia.
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GBM Glomerular basement membrane
GFP Green fluorescent protein
HHT1 Hereditary Hemorrhagic Telangectasia type 1
HAEC Human artery endothelial cells
HUVEC Human umbilical vein endothelial cell
MFI Mean fluorescence intensity
RGD Tripeptide arginine-glycine-aspartic acid
SMA Smooth muscle actin
SolEng Soluble endoglin
TGF-b Transforming growth factor b
UASMC Umbilical artery smooth muscle cells
VSMC Vascular smooth muscle cells
ZP Zona pellucida
Introduction
The circulatory system is walled off by different cell types,
including vascular mural cells and podocytes. Blood vessels
are composed of two cell types: endothelial cells (ECs) and
mural cells which are commonly subdivided into vascular
smooth muscle cells (VSMCs) and pericytes [1]. The
recruitment of pericytes and VSMCs along the endothelial
tube networks represents a critical event controlling capil-
lary remodeling, maturation and stabilization [2, 3]. Overall,
vascular mural cells have demonstrated to be important for
angiogenesis, structural integrity of the microvasculature
and blood flow regulation. Several cytokines are involved in
the regulation of mural cell function [4]. Secretion by ECs of
platelet-derived growth factor (PDGF) regulates pericyte
recruitment to vessels and vascular pattern formation [5, 6].
Also, CXCL12, upregulated by hypoxia [7], promotes
recruitment, vascular remodeling and differentiation of
pericytes [8, 9]. Transforming growth factor-b (TGF-b) is
expressed by ECs and pericytes during angiogenesis, and its
signaling pathway is essential for pericyte differentiation
and recruitment to nascent vessels, as well as for vessel
maturation [10]. Mural and endothelial cells express several
members of the integrin adhesion family of proteins, which
are involved in cell–cell and cell–matrix adhesion processes
required for angiogenesis, vascular stability and vessel
maturation [11, 12]. Moreover, b1 integrin family members,
including the fibronectin receptor a5b1, can be activated by
proangiogenic chemokines such as CXCL12 and are major
determinants of the mural cell phenotype, controlling cell
adhesion, spreading, and blood vessel wall stability [13–16].
Podocytes (or glomerular visceral epithelial cells) are
another type of mural cells, located in the glomerular tuft of
the kidney, that wrap around the capillaries of the
glomerulus, contribute to capillary stabilization and retain
large proteins in the blood by impeding its filtration through
the wall of glomerular capillaries to the Bowman’s space.
Podocytes are exposed to considerable mechanical stress
produced by the plasma filtration [17] and to maintain a
functional filtration barrier, they must adhere strongly to the
glomerular basement membrane (GBM) [18, 19]. Podocyte
adhesion is mediated, at least, by the extracellular engage-
ment of integrin a3b1 to the GBM component laminin-
52117. In spite of the emerging relevant role of integrins, as
cell adhesion receptors in vascular biology [11, 13, 20], their
involvement in the interaction between ECs and mural cells
remains largely unexplored.
Endoglin (Eng) is an endothelial membrane receptor
that, in addition to act as an auxiliary partner protein in the
TGF-b receptor complex, can function as a ligand for
leukocyte integrins [16, 21]. Structurally, the extracellular
region of endoglin contains two distinct domains: (1) a
zona pellucida (ZP) juxtamembrane domain that in human
endoglin displays the prototypic arginine-glycine-aspartic
acid (RGD) motif involved in integrin-based interactions
[16, 22, 23]; and (2) the NH2-terminal orphan domain
involved in binding to BMP9, a member of the TGF-b
superfamily [23–25]. Endoglin is highly expressed by ECs
during neoangiogenic processes at the same time as mural
cells recruitment to vessels occurs, and plays a critical
physiological role in the cardiovascular system [21].
Mutations in the endoglin gene are responsible for a vas-
cular disorder known as Hereditary Hemorrhagic
Telangectasia type 1 (HHT1) characterized by recurrent
epistaxis, telangiectasia and arteriovenous malformations
[26, 27]. Several lines of experimental evidence support the
involvement of endoglin in the mural cell recruitment to
ECs: (1) mice lacking endoglin die by gestational day 11.5
from defective vascular development [28–30]; (2) loss of
endoglin in these Eng-/- mice causes poor vascular
smooth muscle development and arrested endothelial
remodeling [28, 31], suggesting that VSMCs play a role in
regulating endothelial organization and is involved in the
pathogenesis of HHT1; and (3) thalidomide is used to treat
the epistaxis of HHT patients through a mechanism
involving the activation of mural cells, leading to the
embracing and stabilization of small blood vessels [32].
Moreover, endoglin cleavage produced by MMP14 at a
juxtamembrane site gives rise to the soluble form of
endoglin (SolEng) whose levels are significantly increased
in preeclampsia [33], a systemic syndrome of pregnancy
clinically characterized by hypertension, proteinuria and
high levels of SolEng in plasma and urine [34, 35].
Podocyturia has been reported in patients with
preeclampsia, although the underlying mechanism of this
observation remains to be elucidated [36, 37].
Pericytes, VSMCs and podocytes have in common that
they wall off the circulatory system via integrins. Based on
the physical and functional association between endoglin
and b1 integrins [16, 38, 39], our working hypothesis is
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that endoglin may act as an adhesion molecule involved in
the integrin-mediated binding of vascular mural cells and
podocytes. Here, we find that membrane and SolEng reg-
ulate these adhesion processes by interacting with b1-
integrins, at least, via its RGD motif. These results provide
a better understanding on the mechanisms of vessel
development and maturation in vascular pathophysiology,
including preeclampsia and HHT1.
Materials and methods
Cell lines, primary cultures, antibodies and other
reagents
The Jurkat (T cell lymphoblast-like) cell line was cultured
in RPMI 1640 supplemented with 10 % heat inactivated
fetal calf serum (FCS). Human umbilical vein endothelial
cells (HUVECs), and human aortic endothelial cells
(HAECs) (Lonza, Walkersville, USA) were grown on
gelatin (Sigma) coated wells using EBM-2 medium, sup-
plemented with EGM-2 SingleQuots (Lonza) and 10 %
FCS. Umbilical artery smooth muscle cells (UASMCs;
Lonza) were grown in SmGM2 bullet kit medium (Lonza),
supplemented with 10 % FCS. Endothelial colony-forming
cells (ECFCs) exhibit features of a true endothelial pro-
genitor population [40, 41]. ECFCs were isolated as
described [40–42], and grown on gelatin coated wells using
EBM-2 medium, supplemented by 20 % FCS and by
EGM-2 SingleQuots (Lonza). Bone marrow-derived mes-
enchymal progenitor cells (bmMPCs) [43, 44] were grown
on fibronectin (Millipore) coated wells using EBM-2
medium, supplemented by 20 % FCS, rhFGF-B, R3-IGF-1,
ascorbic acid, and GA-1000 (Lonza). bmMPCs were dif-
ferentiated into pericytes by seeding bmMPCs together
with ECFCs at a ratio 1:1 at a total density of 104 cells/cm2
on fibronectin-coated plates in EBM-2 medium containing
20 % FCS. All cell types were cultured in a 5 % CO2
atmosphere at 37 C. Antibodies, RGD-related peptides
and recombinant proteins are described in Online Resource
Supplemental Material.
Expression and silencing vectors and cell
transfections
The expression vector encoding HA-tagged full length
endoglin and the derived truncated construct 437/586-Endo
in pDisplay (Invitrogen) have been previously reported
[45]. The pCEXV-EndoL plasmid, encoding human L-en-
doglin [46], was used to derive by PCR amplification a
truncated endoglin construct containing the zona pellucida
domain (ZPD; amino acids 340–658). The resulting ZPD-
Endo-pDisplay vector was used to generate, by site
directed mutagenesis a mutant of the RGD motif, where the
Asp401 residue is replaced by Ala, leading to the ZPD-
Endo-RGA-pDisplay vector. All endoglin constructs
expressed from pDisplay contain the influenza hemagglu-
tinin epitope HA at the NH2 terminus. To silence endoglin
expression, siRNAs (s4677 and s4679) and scrambled
siRNAs (AM4611 and AM4613), as negative controls
(Ambion, Life Technology), were used. Nucleofections
with expression and silencing vectors were performed
following the manufacturer’s instructions with Amaxa
nucleofector kits VCA-1003 (Jurkat cell line), VPB-1002
(HUVECs), and VPI-1004 (UASMCs) from Lonza using
the Nucleofector I (AMAXA, Germany). Silencing exper-
iments were carried out by simultaneously nucleofecting
two endoglin siRNAs (s4677 and s4679) using scrambled
siRNAs #1 (AM4611) and #2 (AM4613), as negative
controls. Alternatively, silencing of endoglin was per-
formed using endoglin siRNA (sc-35302; Santa Cruz
Biotech) and scrambled siRNA (AllStars; Qiagen
#1027280), as a negative control, in the presence of Pri-
meFect siRNA transfection reagent and PrimeFect diluent
(PA3269 and PA3271; Lonza). Silencing of b1 integrin
was performed using b1 integrin siRNA (sc-35674; Santa
Cruz Biotech) and scrambled siRNA (AllStars; Qiagen
#1027280), as a negative control, in the presence of Pri-
meFect siRNA transfection reagent and PrimeFect diluent
(PA3269 and PA3271; Lonza). To monitor the suppression
efficiency, immunofluorescence flow cytometry to detect
endoglin or b1 integrin expression was performed.
Binding assays of SolEng to cells
The chimeric construct EndoEC-Fc, encoding the extra-
cellular domain of endoglin fused to the Fc fragment of
IgG has been described [47]. Exponentially growing
UASMCs were incubated either in the presence or absence
of CXCL12 (200 ng/mL) or MnCl2 (200 lM) for 20 min at
37 C. Cells were washed with PBS and incubated with
different combinations of EndoEC-Fc, RGD peptide
(1 mM) or DGR peptide (1 mM) in 2 % AB? human
serum for 10 min at 37 C. Samples were then incubated
with FITC-labeled secondary antibody anti-human IgG for
1 h at 4 C, washed with PBS and fixed with 10 %
formaldehyde. The Vectashield mounting medium for flu-
orescence with DAPI (H-1200, Vector) was used to
counterstain the samples and analyze them by confocal
microscopy (Confocal Laser Scanning Microscope, CLSM,
Leica TCS SP5) and video recording (Leica Las AF Lite).
Immunofluorescence flow cytometry
Cells in suspension were incubated for 30 min at 4 C with
2 % human AB? serum and then for 1 h at 4 C with the
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primary antibody. After two washes with cold PBS, sam-
ples were incubated with the secondary antibody (Alexa
488 anti-mouse). Finally, cells were washed twice, and
their mean fluorescence intensity (MFI) was measured in a
Coulter Epics XL flow cytometer (Beckman Coulter).
When necessary, cells nucleofected with green fluorescent
protein (GFP) were also analyzed by fluorescence flow
cytometry. For double fluorescence analysis, cells were
selected on basis of forward and side scatter characteristics
and the results were represented in a dot plot showing
events (cells) for the two fluorescence signals (675 nm for
Alexa 647 and 525 nm for GFP), using an FC-500 flow
cytometer (Beckman Coulter).
Immunofluorescence of 2D co-culture
Culture chamber slides were coated with fibronectin and
seeded with ECFC and bmMPC at a 1:1 ratio. After in vitro
co-culture for 7 days, bmMPC differentiate into VSMC/
pericytes [43]. Once differentiated, cells were fixed with
cold pure methanol on ice for 10 min. For immunostaining
of ECFC, samples were incubated with a mAb anti-human
von Willebrand factor (Dako) for 1 h at room temperature,
followed by incubation with the secondary antibody Texas
Red anti-mouse IgG (Vector) for 1 h at room temperature.
Differentiated bmMPCs were incubated with anti-human
calponin (Abcam), anti-human Sm22a (Abcam), anti-
PDGFRb (Santa Cruz), anti-human NG2 (R&D Systems),
anti-human aSMA (Sigma) or a negative control antibody
(Santa Cruz). After washing samples were incubated with
the appropriate FITC-labeled secondary antibody, and
mounted using Vectashield with DAPI (Vector).
Cell adhesion assays
Cultures of UASMCs in 24-well plates were used as a cell
substrate in adhesion assays with the Jurkat cell line. When
UASMCs were 90 % confluent, Jurkat cells nucleofected
with human endoglin and GFP constructs were added to the
wells. After 1-h incubation, wells were rinsed with PBS and
photographed by confocal microscopy. Then, bound cells
were lysed and their fluorescence was measured. When
necessary, UASMCs were stained with a red vital stain
(CellTrackerTM Red CMTPX, Life Technologies) for
30 min at 37 C, and then washed with PBS prior to the cell
adhesion assay. The quantification of substrate adherence
capacity was carried out by a fluorescent analyser (Var-
ioskan Thermo-Fisher Scientific), selecting the appropriate
wavelength (GFP 494–515 nm). A similar method was used
to quantify the adhesion of pericytes to endothelial cells.
Briefly, HUVEC monolayers or pericyte monolayers
stained with CMTPX were incubated with pericytes or
HUVECs, respectively, previously labeled with the green
stain CSFE (CellTrackerTM, Life Technologies) in the
presence or in the absence of SolEng (50 ng/mL), CXCL12
(100 ng/mL), RGD, RGDK, or DGR peptides (1 mM), or
MnCl2 (200 ng/mL). After 1 h of incubation, wells were
subjected to lysis and adhesion of pericytes to HUVECs was
measured using the Varioskan equipment selecting the
appropriate wavelength (CSFE: 494–515 nm). Images of
cell–cell adhesion were obtained by confocal microscopy
(Confocal Laser Scanning Microscope, CLSM, Leica TCS
SP5). Quantification of bound cells was carried out by
measuring the surface area of the cells using ImageJ Ver-
sion 1.46 software. When required, UASMCs or HAECs
were preincubated with 100 ng/mL CXCL12 for 30 min at
37 C, prior to CSFE labeling and cell adhesion assays. The
concentrations of cycloheximide and monensin were
selected from an initial dose-dependent study to exclude
possible toxic effects of the drugs.
Phosphorylation and western blot studies
Individual and combined cultures of UASMCs and HAECs
were incubated in the absence or presence of 1 lg/mL
SolEng. At different time points, adherent cells were lysed in
RIPA buffer, and proteins were subjected to SDS-PAGE and
transferred to nitrocellulose. Themembraneswere incubated
with the primary antibodies anti-p-FAK (Tyr925; BD Bio-
sciences), anti-p-Akt (Ser473; Cell Signalling) and anti-
actin (Sigma). Immunoreactive bands were visualized using
enhanced chemiluminescence detection reagents (Pierce).
Images of chemiluminescent signals were captured using
G:BOX Chemi XT16 Image Systems and quantified using
Gene Tools version 4.0.0.0 (Syngene). The presence of HA-
tagged SolEng in concentrated urine samples was detected
byWestern blot analysis with anti-endoglin (P4A4) and anti-
HA antibodies. Endoglin protein bands were visualized with
a ChemiDocTM XRS? equipment (Bio-Rad) and their
intensity was quantified using Image LabTM software.
3D coculture of vascular ECs and mural cells
3D cocultures of endothelial cells and UASMCs at a 4:1
ratio, respectively, were performed using Matrigel (BD
Bioscience). When necessary, ECs stained in red (CMTPX)
and UASMCs stained in green (CSFE) were co-cultured.
Similarly, HUVECs, HAECs, or UASMCs nucleofected
with siRNA/GFP were resuspended and cocultured in
Matrigel. Endothelial cells (HUVECs/HAECs/ECFCs) and
mural cells (UASMC, bmMPC) were resuspended in a
mixture of Matrigel:Medium (1:1) in a total volume of
100 lL/well. For in vitro assays, 4-well glass slides with a
1.7 cm2 growing area per well (Millipore) were used.
Additives were added at time 0 and cocultures were
monitored for 6 h at 37 C. After 4 h of incubation,
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photographs of the slides were taken. For studying the
potential role of integrins we used the anti-b1 mAbs TS2/
16 and LIA1/2. As a global integrin activator MnCl2 at
200 lM was used. The macrocyclic compound AMD3100
octahydrochloride (Sigma-Aldrich), inhibitor of the
CXCR4 alpha-chemokine receptor (5 lM), human SolEng
(1 lg/mL), RGD (Arg-Gly-Asp; 1 mM), PDGF-BB
(10 ng/mL) and CXCL12 (200 ng/mL) were also used.
Immunohistochemistry and ELISA
Sections (3 lm) from kidneys, lungs and Matrigel plugs
were cut and stained with hematoxylin and eosin or with
Masson’s trichrome stain. For immunohistochemical
analysis, sections were deparaffinated in xylene and rehy-
drated in a graded series of ethanol. The antigen-retrieval
process was carried out by a 3-min microwave incubation
of sections with citrate solution (BioGenex). Endogenous
peroxidase was blocked by incubation in 3 % hydrogen
peroxide and sections were incubated with anti-aSMA
(Leica Biosystems), anti-podocin (Abcam), anti-Willms
Tumor (WT1) (sc-192; Santa Cruz Biotechnology), anti-
CD31 (Leica Biosystems), mouse monoclonal anti-CD105
(Dako) or anti-CD68 (Dako). Then, sections were washed
in PBS and incubated with the Novolink Polymer Detec-
tion System (Novocastra), followed by reaction with
3,30diaminobenzidine as chromogen. Negative controls
were performed in the absence of the primary antibody. For
ThinPrep cytology, urine cytological slides were prepared
by using a liquid-based method technique following the
manufacturer’s guidelines (ThinPrep 2000; Cytyc) and
stained using either the standard hematoxylin technique or
immunohistochemistry against aSMA as above. Urine
samples were used to determine the concentration of
SolEng (R&D Systems), nephrin (Exocell) and podoca-
lyxin (Wuhan EIAAB Science), using ELISA kits.
Mice and in vivo assays
For Matrigel plug assays, ECFCs and bmMPCs (1:1 ratio;
total cells 3 9 106) were resuspended in 200 lL of
Matrigel (BD Bioscience) either in the absence or in the
presence of human SolEng and subcutaneously injected
into 6-week-old male nude mice (n = 13). Parallel assays
were carried out in the absence of cells. After 7 days, intact
Matrigel plugs were carefully exposed, fixed, and embed-
ded in paraffin for histological examination. Three different
sections of each plug were analyzed and blood vessels were
quantified by hematoxylin and eosin staining. Transgenic
C57BL/6J mice (12–20 weeks of age) with recurrent
backcrossing, expressing an HA-tagged soluble form of
endoglin, driven by a ubiquitous actin promoter (Sol.Eng?)
[35], were used for immunohistochemistry of the kidney
and lung. Representative tissue stainings of Sol.Eng?
(n = 17) and WT (n = 17) mice are shown in the figures.
Urine from Sol.Eng? (n = 10) and WT (n = 10) mice was
collected in metabolic cages or obtained directly from the
bladder. Urinary cytology was performed using the Thin-
Prep technique. The concentration of endoglin and the
podocyte markers nephrin and podocalyxin was measured
by ELISA and urinary cells were stained with podocyte-
specific antibodies. Vascular permeability studies were
carried out in Eng?/- mice and their Eng?/? littermates
[29, 48]. Mice were anesthetized with 1.2 % isoflurane and
perfused through the jugular vein with a solution of fluo-
rescein isothiocyanate-dextran (FITC-dextran;
2 9 106 kDa; Sigma-Aldrich) at 100 mg/kg body weight.
After 2 h, mice were killed by cervical dislocation and eyes
were removed and fixed in 4 % paraformaldehyde for 1 h.
Eyes were dissected and the neuroretinas (n = 19) were
isolated and mounted with antifade solution (ProLong gold,
Life Technologies). Retinas were photographed using a
fluorescence microscope (Axiovert 200 M, Zeiss). All
procedures were approved by the Animal Care and Use
Committees of the University of Salamanca and University
of Paris. Also, mice were cared for in accordance with the
standards established in the National Institutes of Health
Guide for the Care and Use of Laboratory Animals.
Cell quantification and statistical analysis
Binding of UASMCs to HUVECs in angiogenesis assays
was quantified by measuring the intensity profile using flu-
orescence confocal microscopy (SP5, Leica). Fluorescence
images were transformed in binary system by ImageJ to
quantify the percentage of cell adhesion. In adhesion assays,
bound fluorescently labeled cells were lysed and quantifi-
cation was carried out using a Varioskan plate reader. All
values are expressed as mean ± standard deviation. Results
are representative of, at least, five independent experiments
in triplicate samples. Statistical analysis was performed
using a one-way ANOVA and Bonferroni post-test. A value
of p\ 0.05 (*) was considered statistically significant and a
value of p\ 0.005 (**) or p\ 0.001 (***) was considered
statistically highly significant.
An expanded ‘‘Materials and methods’’ section is
included in the Online Resource Supplemental Material.
Results
Endoglin is involved in the interaction
between endothelial and mural cells
We have previously demonstrated that endothelial endoglin
is involved in integrin-mediated cell adhesion [16]. To
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assess whether endoglin is involved in adhesion between
endothelial cells and mural cells, endoglin suppression
experiments were carried out (Fig. 1). Transfection of cells
with siRNA for endoglin was monitored by using a GFP
expression vector (Fig. 1a) as well as by immunofluores-
cence flow cytometry using antibodies to endoglin
(Fig. 1b). Endoglin was found to be expressed at the sur-
face of cultured endothelial cells (HAEC, human aortic
endothelial cells; and HUVEC, human umbilical vein
endothelial cell) and umbilical artery smooth muscle cells
(UASMCs) (Fig. 1b, left panels). Noteworthy, basal
endoglin expression levels were much higher in cultured
HUVECs or HAECs than in UASMCs or bmMPCs
(Fig. 1b; Online Resource Supplemental Fig. 1B, C). As
previously reported for HUVECs [49], wound healing
assays of HAECs showed an upregulated expression of
endoglin upon injury of the cell monolayer (at 6 and 12 h;
Online Resource Supplemental Fig. 1). By contrast, similar
wound healing assays in UASMCs did not affect endoglin
levels, whereas bmMPCs displayed only a slight increase at
24 h (Online Resource Supplemental Fig. 1). Upon treat-
ment with specific siRNA (Fig. 1b, right panels), endoglin
expression was silenced in HUVECs (20.9-fold reduction;
MFI, 23.06 vs. 1.1), HAECs (5.1-fold reduction; MFI, 3.07
vs. 0.6) and UASMCs (8.3-fold reduction; MFI, 15.8 vs.
1.9). As a negative control, transfection with two different
scrambled siRNA did not affect endoglin expression levels
compared to untreated cells. No significant differences in
endoglin silencing efficiency were observed between early
passages (p2–4) vs. late passages (p8–10) of these cultured
cells. The vast majority of HUVECs cotransfected with
GFP and endoglin siRNA expressed both GFP and down-
regulated endoglin. It has been shown that endoglin plays a
crucial role in in vitro and in vivo angiogenesis [21, 30,
50]. To assess whether the endoglin suppression achieved
in ECs was associated with a decreased endoglin-depen-
dent function, tubulogenesis (a hallmark function of ECs)
assays in matrigel were carried out. Figure 1c shows that
silencing of endoglin with siRNA in HUVECs and HAECs
leads to an impaired tube formation respect to cells trans-
fected with scrambled siRNA or untreated cells. As
expected, addition of SolEng (1 lg/mL) also interfered
with this angiogenesis assay, in agreement with previous
reports [24, 34], suggesting that SolEng counteracts the
normal function of membrane bound endoglin. The for-
mation of blood vessels is initiated by endothelial
tubulogenesis, followed by the recruitment of mural cells.
To assess the role of endoglin in the interaction between
endothelial cells and mural cells, these two cell populations
were used in 3D tubulogenesis assays. To visualize the
cellular adhesion, UASMCs were labeled with GFP and
then cocultured with HUVECs at a 1:4 ratio. Adhesion of
mural cells to endothelial cells was clearly inhibited by
SolEng as well as by suppressing endoglin expression in
HUVECs, in UASMCs or simultaneously in both cell types
(Fig. 2a, b). High magnification photographs clearly
showed binding of green-labeled UASMCs to EC tubules,
but not to the surrounding extracellular matrix (ECM)
excluding a relevant contribution of cell adhesion to the
substrate (Online Resource Supplemental Fig. 2A). Tubu-
logenesis studies in matrigel also showed that SolEng was
able to abrogate the adhesion of UASMCs to HAECs
(Online Resource Supplemental Fig. 2A). These data sug-
gest that endoglin is involved in the interaction between
endothelial cells and mural cells. Interestingly, silencing of
endoglin in mural cells led to an important reduction in
VSMC adhesion to ECs (from 32 to 2.2 %). Endoglin
expression in resting VSMCs in vivo is relatively low,
while it is upregulated under inflammatory conditions or
upon in vitro culture [51–53], suggesting that our in vitro
model somehow mimics endoglin function in inflamma-
tion. Overall, suppression of membrane endoglin, or
addition of SolEng, induced a change in the morphology of
ECs and VSMCs making them more round, further sup-
porting the role of endoglin in cell adhesion (Fig. 2c, d).
Adhesion of CSFE-labeled VSMCs was clearly abolished
in the presence of SolEng. Furthermore, adhesion experi-
ments of UASMCs to HAECs, representative ECs typically
enveloped by VSMCs, clearly showed the involvement of
endoglin in the interaction between ECs and mural cells
using SolEng or endoglin siRNA (Online Resource
cFig. 1 Endoglin silencing in endothelial and smooth muscle cells.
a Primary cultures of HUVECs, HAECs and UASMCs (p4–8) were
untreated (control), nucleofected with endoglin (Eng) specific siRNA
(#s4677 and #s4679) and GFP (green stain), or nucleofected with
scrambled siRNA (#AM4611 and #AM4613) and GFP (siRNA
control). After 48 h, cells were observed by confocal microscopy.
Cells cotransfected with GFP are visualized by their green fluores-
cence. b Flow cytometry analysis. Primary cultures of HUVECs,
HAECs and UASMCs were untreated (control) or nucleofected with
Eng siRNA or scrambled siRNA #AM4611 and #AM4613 (siRNA
control). After 48 h, cells were analyzed by immunofluorescence flow
cytometry with anti-endoglin mAb P4A4 (green histograms) or a
negative control mAb (X63; blue histograms). The mean fluorescence
intensity (MFI) of each sample is indicated. Endoglin expression is
decreased upon transfection with specific siRNA in all cells. Cells
nucleofected with scrambled siRNA showed the same endoglin
expression levels as untreated cells (data not shown). c HUVECs and
HAECs were incubated in matrigel to analyze tube formation.
Confocal microscopy of untreated cells (control), nucleofected for
48 h with scrambled siRNA (AM4611, #1; AM4613, #2) or Eng
siRNA (#s4677 and #s4679), or incubated with soluble endoglin
(Sol.Eng) are shown. The histogram on the right indicates the
percentage, respect to the control sample (100 %), of closing tubes
under each experimental condition. Samples were in triplicates and
the mean of the control condition was given the arbitrary value of
100. The average of five different experiments is shown. The
statistical significance respect to control value (CTR) is indicated
(***p\ 0.001)
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Supplemental Fig. 3). Together, these data suggest that
endoglin is involved in the interaction between endothelial
and mural cells.
Integrins are involved in the interaction
between endothelial cells and mural cells
Because endothelial endoglin is a ligand for b1 integrins
[16] and VSMCs, pericytes and podocytes express b1
integrins [13, 19], we next assessed whether these receptors
were involved in adhesion of mural cells to endothelial
cells, using specific antibodies and activators. Thus,
adhesion of UASMCs to HUVECs in matrigel plates was
clearly inhibited in the presence of the blocking anti-b1
mAb LIA1/2 (Fig. 3a, b), whereas the non-inhibitory anti-
b1 mAb TS2/16, did not affect adhesion. By contrast,
MnCl2, a global activator of integrin activity, induced an
enhanced cell adhesion between ECs and VSMCs. Fur-
thermore, the chemokine CXCL12 that activates integrins,
allowing their binding to endoglin [16], clearly enhanced
adhesion of UASMCs to HUVECs in matrigel (Fig. 3c, d).
The effect of CXCL12 is likely mediated by the chemokine
specific receptor CXCR4, whose expression could be
detected at the cell surface of UASMCs (Online Resource
Supplemental Fig. 2B, C). Interestingly, PDGF-BB, a well
known mural cell recruiter to vessels, whose expression is
induced by CXCL12 [8], markedly increased the adhesion
between UASMCs and HUVECs. In addition, CXCL12-
and PDGF-dependent cell adhesion was abolished in the
presence of AMD3100, an inhibitor of the CXCL12/
CXCR4 pathway (Fig. 3c, d), supporting the critical role of
CXCL12-dependent integrin activation in these assays.
Adhesion studies of UASMCs to HAECs also showed an
enhanced cellular adhesion in the presence of CXCL12
(Online Resource Supplemental Fig. 2A). Adhesion by
means of b1-integrins is known to induce phosphorylation
of protein kinases Akt and FAK. Importantly, addition of
SolEng to UASMCs alone or in co-culture with HAECs led
to an increased phosphorylation of Akt and FAK, an effect
that was inhibited by siRNA-mediated depletion of b1-
integrin (Fig. 3e–h). However, addition of SolEng to
individual cultures of HAECs did not induce phosphory-
lation of either Akt or FAK, suggesting that SolEng
specifically targets integrins on UASMCs. Furthermore,
basal and CXCL12-induced adhesion between UASMCs to
HAECs were abolished upon siRNA-mediated knockdown
of b1-integrin in UASMCs (Fig. 4).
Role of the RGD motif of endoglin in the adhesion
between ECs and VSMCs
To investigate the possible involvement of endoglin in the
CXCL12-dependent integrin activation for cell adhesion,
additional experiments in the presence of SolEng and RGD
peptides were carried out. In agreement with the matrigel
assays of Fig. 3, adhesion of HUVECs to UASMCs
monolayers was markedly enhanced by addition of
CXCL12 and this increase was abolished by the presence
of SolEng (Fig. 5a). Of note, SolEng has been previously
shown to specifically inhibit the interaction between
endothelial endoglin and leukocyte integrins [16]. As a
positive control, incubation with thalidomide increased
HUVECs adhesion to mural cells in agreement with a
previous report [32]. Similar results as in Fig. 5a were
obtained with the reverse experiment, i.e., adhesion of
VSMCs to ECs monolayer (Fig. 2c, d). Next, we investi-
gated the possible involvement of endoglin’s RGD as a
recognition motif of b1 integrins in VSMCs. The RGD
motif is contained within the juxtamembrane ZP domain of
endoglin (Fig. 5c) in an accessible hydrophilic region of
the protein [22]. As shown in Fig. 5a, addition of the
human endoglin-derived DRGDK peptide inhibited the
adhesion of HUVECs to UASMCs monolayers, whereas
the negative control peptide SDGRG did not affect cell
adhesion, suggesting that the RGD motif of endoglin is
involved in the binding to b1 integrins in VSMCs. To
further investigate the adhesive capacity of the RGD motif
of endoglin, different deletion and mutant constructs were
used in presence of CXCL12 (Fig. 5b, d, e). The activity in
cell adhesion of these constructs was assayed by trans-
fecting them into Jurkat cells followed by incubation with
an UASMC monolayers (Fig. 5e, f). Jurkat cells were
selected because they do not express endogenous endoglin,
grow in suspension and show a negligible adhesion to
UASMCs under basal conditions. Upon cell transfection,
cFig. 2 Role of endoglin in adhesion between VSMCs and ECs. a,
b Cell–cell adhesion in angiogenesis assays. a UASMCs were
transfected with GFP and cocultured with unlabeled HUVECs at a 1:4
ratio in matrigel to analyze mural cell adhesion to ECs. Confocal
microscopy of untreated cells (control) and cells incubated with
soluble endoglin (Sol.Eng) or nucleofected with Eng siRNA are
shown in representative photographs. The intensity of the staining
according to the color scale (0–250) indicates mural cell adhesion to
endothelial cells in 3D co-culture b Quantification of UASMCs
binding to ECs was carried out by measuring the intensity profile
using fluorescence confocal microscopy (SP5, Leica). The mean area
in percentage, representing mural cell adhesion measured in different
fields, is indicated. Samples were in triplicates and the mean of the
control condition was given the arbitrary value of 100. The average of
five different experiments is shown. c, d Cell adhesion assay.
c HUVEC monolayers were incubated with UASMCs previously
labeled with CSFE in the absence or in the presence of soluble
endoglin. After 1 h incubation, wells were washed and the cells were
visualized by confocal microscopy. d Binding of UASMCs to
HUVECs in c was quantified by measuring the intensity profile using
fluorescence confocal microscopy (SP5, Leica). The average of four
independent experiments is shown. The statistical significance respect
to control value (CTR) is indicated. *p\ 0.05; **p\ 0.005;
***p\ 0.001
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recombinant endoglin proteins were easily detected by
western blot and immunofluorescence flow cytometry
analyses (Online Resource Supplemental Fig. 4). Expres-
sion of full length endoglin or a truncated endoglin
construct with the RGD-containing ZP domain (ZPD-
Endo) dramatically increased adhesion of Jurkat cells to
UASMCs (Fig. 5b, e). By contrast, expression of the ZP
domain with an inactive mutant version of the RGD motif
(ZPD-Endo-RGA) or an RGD-less shorter construct con-
taining the carboxy-terminal ZP subdomain (437/586-
Endo) showed a marked reduction (62 and 76 %, respec-
tively), in the adhesion of Jurkat cells to UASMCs respect
to cells transfected with the endoglin full length construct.
Together, these results suggest that the RGD motif of
membrane endoglin is involved, via integrins, in the
binding to VSMCs.
Binding of SolEng to VSMCs and its in vivo effect
The experiments shown in Figs. 2, 3 and 4 indicate that
SolEng can inhibit the integrin-mediated interaction
between ECs and mural cells. We then wondered whether
this inhibitory effect involved a stable binding of SolEng to
VSMCs. To assess this binding, a chimeric protein con-
taining the extracellular domain of endoglin fused to the
human Fc fragment [47] was used. As shown in Fig. 6a,
binding of SolEng to untreated VSMCs was markedly
enhanced in the presence of the integrin activators
CXCL12 and MnCl2, suggesting that SolEng stably binds
to activated integrins on the cell surface (Online Resource
Supplemental Material, Video #1). Of note, SolEng-treated
cells slightly changed their morphology and clustered
(Fig. 6a), a phenomenon likely involving integrins-medi-
ated cell interactions with the ECM proteins. To assess the
effect of SolEng in vivo, a well-established differentiation
protocol involving the co-culture of human bone marrow
mesenchymal precursor cells (bmMPC) and human cord
blood-derived endothelial colony forming cells (ECFC)
was used [43]. Upon co-culture for 7 days, ECFC induce
bmMPC differentiation into VSMCs/pericytes and specific
markers were detected, including aSMA, PDGFRb, NG2,
Calponin I and Sm22a (Fig. 6b). As expected, ECs also
expressed the endothelial-specific von Willebrand factor
(Fig. 6b), as well as endoglin (Online Resource Supple-
mental Fig. 5A). Then, nude mice were injected with these
co-cultures in matrigel in the absence or in the presence of
SolEng and after 1 week, the plugs were analyzed (Fig. 6c,
d). Hematoxylin and eosin staining of the plugs revealed
that SolEng inhibits the angiogenic process (Fig. 6e, f),
suggesting again that SolEng impairs the assembly of ECs
and mural cells, thus interfering with the tubulogenesis
process (Fig. 6g; Online Resource Supplemental Fig. 5B).
The involvement of membrane bound endoglin and b1-
integrin in the in vivo model of tubulogenesis was further
supported by siRNA-mediated suppression experiments
(Fig. 7). The expression of endoglin or b1-integrin in
ECFC or bmMPC, respectively, was knockdown in vitro by
siRNA (Fig. 7a), leading to a markedly reduced number of
vessels in vivo, compared to controls (Fig. 7b, c). These
results suggest that endoglin in ECFC and b1-integrin in
bmMPC are necessary for the proper assembly of ECs and
mural cells in vivo.
Endoglin deficiency leads to an increased
pericyte-dependent EC permeability
Pericytes embracing the endothelium regulate the blood
retinal barrier. Vascular permeability studies were carried
out in endoglin heterozygous mice (Eng?/-), as a model of
HHT1 [29]. Measured by passage of fluorescent dextran,
the retinas from Eng?/- mice (n = 8) displayed a higher
number of permeabilization foci (Fig. 8, arrows) compared
to Eng?/? retinas (n = 10), suggesting a destabilization of
the endothelial barrier function due to endoglin haploin-
sufficiency (Fig. 8a, b). These results support our
hypothesis that endoglin is involved in the adhesion
between ECs and pericytes and consequently in vessel
stabilization. Of note, the increased vascular permeability
in the neuroretina (Fig. 8) is compatible with the decreased
inflammation-induced transendothelial migration of
leukocytes [16] observed in Eng?/- mice, as well as with
cFig. 3 Role of integrins in adhesion between VSMCs and ECs.
UASMCs were labeled with CSFE (green) and HUVECs were
labeled with CMTPX (red). Then, UASMCs were cocultured with
HUVECs at a 1:4 ratio in matrigel to analyze mural cell adhesion to
ECs. a, c Representative photographs of confocal microscopy
analysis. a Cells treated with a control mAb IgG2b (CTR) and cells
incubated with the inhibitory anti-b1 integrins mAb LIA1/2, the anti-
b1 integrins mAb TS2/16 or the general integrins activator MnCl2.
c Untreated cells (control) and cells incubated with the pericyte
recruiter PDGF-BB or the integrins activator CXCL12 either in the
absence or in the presence of the chemokine receptor (CXCR4)
inhibitor AMD3100 (AMD). b, d Quantification of UASMCs binding
to HUVECs from a and c, respectively. The intensity profile was
measured using fluorescence confocal microscopy (SP5, Leica). The
mean area in percentage, representing mural cell adhesion measured
in different fields, is indicated. Histograms in b and d represent the
mean of four and five independent experiments, respectively. The
statistical significance respect to control value (CTR) is indicated.
*p\ 0.05; **p\ 0.005; ns not significant. e–h Effect of soluble
endoglin on Akt and FAK phosphorylation. UASMCs were trans-
fected or not with b1-integrin siRNA or scramble siRNA (scRNA).
Cultures of UASMCs or cocultures of UASMCs and HAECs were
incubated in the absence or presence of 1 lg/mL SolEng. At the times
indicated, adherent cells were lysed and proteins were subjected to
SDS-PAGE, followed by immunodetection with anti-p-FAK
(Tyr925), anti-pAkt (Ser473) or anti-actin antibodies (e). Histograms
represent the p-FAK/actin ratio in UASMCs (f), p-FAK/actin ratio in
UASMCs/HAECs (g) and the p-Akt/actin ratio in UASMCs/HAECs
(h). This is a representative experiment of five different ones
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the leukocyte infiltration detected in glomeruli of Sol.Eng
mice [35]. In this line, vascular permeability is a passive
process that allows plasma to pass through the endothe-
lium, whereas the leukocyte transmigration is an active
process that involves the stimulation of leukocytes by an
inflammatory stimulus, followed by different sequential
highly regulated steps, including rolling, activation, firm
adhesion and transendothelial migration (diapedesis),
respectively.
Effect of SolEng in podocyturia and its involvement
in preeclampsia
In the kidney, podocytes are bound to glomerular basement
membrane (GBM) through several b1 integrins [19].
Because podocyturia is present in patients with
preeclampsia, a disease associated with elevated levels of
SolEng in serum [37], we postulated that SolEng could
contribute to podocyturia by detaching podocytes from
capillaries. To test this hypothesis, transgenic mice
expressing constitutively high levels of human SolEng
(Sol.Eng?), which are a model of preeclampsia [35], were
used. The transgenic SolEng was easily detected in the
urine of Sol.Eng? mice ([15 ng/mL in all animals; n = 9),
whereas it was almost undetectable in wild type animals
(\0.12 ng/mL; n = 4). Staining of glomeruli with anti-
aSMA and the specific markers podocin and Willms
Tumor (WT1) revealed that the number of podocytes is
reduced in Sol.Eng? compared to wild type mice (Fig. 9a,
b). In some cases, a dramatic loss of aSMA and podocin in
Sol.Eng? mice was observed (Online Resource Supple-
mental Fig. 6A, B). Compatible with these findings,
hematoxylin and eosin staining shows an increased number
of cells in the urine of Sol.Eng? vs. WT mice (Fig. 9c, top
panels) and staining with anti-aSMA, anti-podocin and
anti-WT1 indicates the presence of podocytes in the urine
of Sol.Eng? mice (Fig. 9c). Furthermore, the levels of
nephrin and podocalyxin, two markers of podocyturia,
were significantly higher in the urine of Sol.Eng? vs. WT
mice (Fig. 9d). All these data suggest the presence of
podocyturia in Sol.Eng? mice. To support the hypothesis
that SolEng induces the detachment of podocytes and
allows the filtration of large molecules in Sol.Eng? mice,
we analyzed the presence of endoglin in the glomeruli by
IHC and in the urine by western blot. As shown in Online
Resource Supplemental Fig. 6C, D, a marked endoglin
staining was found in the glomeruli of SolEng? mice and
SolEng was detected by western blot analysis in the urine
of SolEng? mice, while it was absent in WT animals.
Taken together, these results suggest that SolEng is able to
detach podocytes from glomerular capillaries giving rise to
a defect in permeability and vessel stabilization.
Discussion
During blood vessel assembly and maturation, ECs and the
vessel basal membrane recruit different types of mural
cells, including VSMCs and pericytes. Our data suggest
that endothelial endoglin plays a role in the recruitment of
these mural cells and in vessel stabilization. In agreement
with this conclusion, previous reports have shown that in
yolk sacs from endoglin KO mice, the levels of aSMA are
strikingly decreased because of the failure of vascular
VSMCs to differentiate and associate with ECs, so that
blood vessels become fragile and dilated [28, 54]. Of note,
these latter features are the hallmark of vascular lesions in
HHT, a disease originated by heterozygous mutations in
the endoglin gene [27]. In spite of the experimental evi-
dences supporting the role of endoglin in the interplay
between ECs and VSMCs, the molecular bases for the
endoglin involvement are not completely understood.
Endoglin is expressed at high levels in ECs undergoing
active proliferation or angiogenesis [21], while its levels in
VSMCs are very low or undetectable in normal conditions,
but they can be increased upon in vitro culture, during
atherosclerosis or vascular injury [51–53]. Additional dif-
ferences between cultured ECs and vascular mural cells,
regarding basal and stimulated expression levels of endo-
glin, have been observed (Fig. 1b; Online Resource
Supplemental Fig. 1). While the role of endoglin in vas-
cular mural cells deserves an independent analysis, we
have focused our study on the role of endothelial endoglin
in the adhesion between ECs and vascular mural cells
(Fig. 10a–c). Silencing endoglin in ECs (HUVECs and
HAECs) results not only in inhibition of tube formation in
3D matrigel assays, but also in a severely compromised
attachment of UASMC to ECs in 3D co-cultures. These
cFig. 4 Silencing of b1-integrin in UASMCs. Primary cultures of
UASMCs were transfected with beta1 integrin specific siRNA
(siRNA-b1) or scrambled siRNA (scRNA). Transfected UASMCs
were morphologically (a), phenotypically (b) and functionally (c,
d) analyzed. a Untreated UASMCs (control) and cells transfected
scRNA display the same morphology with slight changes respect to
cells transfected with siRNA-b1, likely due to the b1 integrin role in
cell adhesion. b Immunofluorescence flow cytometry with anti-CD29
(anti-b1 integrin) antibodies show a downregulation of b1 integrin
(76 %) in UASMCs transfected with specific siRNA vs. cells
transfected with scrambled siRNA. c Cell–cell adhesion assays.
Confluent monolayers of HAECs were incubated with UASMCs,
previously labeled with CFSE, in the absence (control) or presence of
1 lg/mL SolEng or 100 ng/mL CXCL12, as indicated. After 1 h
incubation, wells were washed and the cells were visualized by
confocal microscopy. d Binding of HAECs to UASMCs in c was
quantified by measuring the fluorescence intensity using Image J and
HistolabTM (Microvision) software. A representative experiment out
of four made in triplicate with similar results is shown (**p\ 0.005;
***p\ 0.001)
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data indicate a critical role for endothelial endoglin in the
interaction between ECs and VSMCs. Moreover, our
results suggest the involvement of the RGD motif of
endoglin in its binding to integrins. Members of the RGD
family of related peptides have in common the presence of
an acidic residue (D or E) that is critically involved in
coordinating a Mg2? cation bound to the MIDAS motif in
integrin b subunits [55] and this acidic residue is conserved
among mammalian endoglins [16]. Of note, the homolo-
gous sequence of the human RGD in mouse endoglin is
TDD a motif that has also been shown to be involved in
integrin-mediated cell adhesion and is present in the dis-
integrin domain of murine ADAM-15 [16, 56].
The specific integrin involved in the binding to endoglin
is likely integrin a5b1, which specifically recognizes the
RGD motif in extracellular matrix proteins and it is
expressed by VSMCs, regulating their adhesion and
recruitment to blood vessels [13]. In fact, the adhesion of
UASMCs to ECs is reduced by suppressing b1-integrin
using specific siRNA and by the b1-integrin inhibitory
antibody LIA1/2. Conversely, incubation with CXCL12, an
activator of integrins markedly enhanced adhesion of
VSMCs to ECs and this effect was abolished in the pres-
ence of SolEng or an endoglin-derived peptide containing
the RGD motif. Interestingly, pretreatment of UASMCs
with the proinflammatory chemokine CXCL12 was suffi-
cient to enhance adhesion to ECs, suggesting that
activation of VSMC integrins promote their binding to
endothelial endoglin. While VSMCs are not typically
considered targets of vascular inflammation [57], endoglin
expression in endothelial cells promotes smooth muscle
precursor cell recruitment and vessel maturation via regu-
lation of the CXCL12/CXCR4 signaling axis [58]. In this
line, our results point out the potential mural cells
responsiveness in an inflammatory setting, at least,
regarding the endoglin/integrin-mediated responses. The
effect on vascular function upon the inducible deletion of
b1 integrin family members has been previously reported.
Thus, the b1-integrin deletion in VSMCs of adult mice
leads to catastrophic effects on the vascular system and the
animal dyes after 10 days of inducing b1-integrin sup-
pression, suggesting that b1-integrin in VSMCs is involved
in vascular function [59]. Moreover, mice lacking the
RGD-binding a5 and av integrins (both partners of b1-
integrin) on VSMCs develop interrupted aortic arches,
large brachiocephalic/carotid artery aneurysms and cardiac
septation defects [60]. These results are in agreement with
our tubulogenesis results demonstrating that b1-integrins in
bmMPC are necessary for the proper assembly of ECs and
mural cells in vivo (Fig. 7). Further support for the
involvement of the endoglin RGD motif was obtained from
cellular adhesion experiments using endoglin mutant con-
structs. Thus, the RGD containing ZP domain was
identified as the region responsible for endoglin binding to
VSMCs. Compatible with these adhesive properties, the ZP
domain is a conserved module for polymerization of
extracellular proteins present in a large family of ZP pro-
teins [61]. However, these experiments do not rule out an
RGD-independent involvement of endoglin in adhesion to
VSMCs. Indeed, treatment with MnCl2, a general activator
of integrins, stimulated adhesion of UASMCs to ECs,
suggesting the involvement of other integrin family mem-
bers as well as non-RGD mediated endoglin interactions
with integrins. This interpretation agrees with co-im-
munoprecipitation experiments between endoglin and the
a5 integrin subunit demonstrating that endoglin can bind to
this integrin independently of the RGD motif [39].
During angiogenesis, the adhesion between ECs and
mural cells is finely regulated by soluble factors, including
PDGF-BB. Once released by activated platelets, PDGF-BB
induces the recruitment of mural cells to endothelial tubes,
although the molecular mechanism of this process is not
fully understood. We find that in tubulogenesis assays, the
PDGF-dependent adhesion of VSMCs to ECs is abolished
by an antagonist of CXCR4, the CXCL12 receptor.
Because CXCL12 is an activator of integrins and induces
cFig. 5 Involvement of the endoglin RGD motif in adhesion between
VSMCs and ECs. a HUVECs, labeled with CSFE (green), were
incubated with the UASMC monolayers for 1 h at 37 C with/without
thalidomide, CXCL12 (CXC), SolEng (S.Eng), RGD peptide or DGR
peptide, as indicated. Bound CSFE-labeled cells were lysed and
quantified by Varioskan plate reader. The average of four different
experiments in duplicate is shown. Statistical significances vs. control
cells (**p\ 0.005) or vs. CXCL12-treated cells (**p\ 0.005; red
asterisks) are indicated. b–e Adhesion of different deletion constructs
of endoglin to VSMCs. c Atomic model for endoglin and location of
RGD motif. The extracellular domain of endoglin contains an orphan
domain (OD) and a juxtamembrane zona pellucida domain (ZPD) that
includes an RGD motif (in magenta). The dashed line separates the
OD from the ZPD. d Generation of different truncated forms of
endoglin. Numbers indicate the amino acid of endoglin (starting at the
N terminus) that limit the corresponding fragment. The position of
extracellular (EC), transmembrane (TM), and cytoplasmic (CT)
domains, is indicated. All of the constructs contain the leader
sequence of the IgGj and the HA epitope at the N terminus (from the
pDisplay vector), and construct 437/586-Endo encode the transmem-
brane domain of the pDisplay vector. The OD encompasses amino
acid residues 26–359, whereas the ZP domain is contained within the
fragment 360–586. The ZPD-C (residues 437–586) is a sub-domain of
ZPD. The presence of the RGD motif (residues 399–401) and its
mutant version (RGA) is indicated. b, e Adhesion assays of Jurkat
cells to VSMCs. Jurkat cells were nucleofected with endoglin, ZPD-
Endo, ZPD-Endo-RGA or 437/586-Endo constructs together with
GFP. As negative controls, cells were nucleofected with GFP in the
absence (CTR) or in the presence of the empty vector (EV). After
nucleofection, Jurkat cells were added to the UASMC monolayers for
1 h at 37 C. Bound GFP expressing cells were lysed and quantified
by Varioskan plate reader (e). A representative experiment out of
three made in triplicate with similar results is shown. Statistical
significances vs. control cells (**p\ 0.005) or cells expressing full
length endoglin (*p\ 0.05; red asterisks) are indicated
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an endoglin-mediated adhesion between ECs and VSMCs
(Fig. 5), these data are compatible with a PDGF-induced
recruitment of mural cells to endothelial tubes mediated by
CXCL12 and endoglin.
The evidences for the role of endoglin in ECs–VSMCs
adhesion found in this work are in agreement with the poor
coverage of vessels by SMCs and with the arrested
endothelial remodeling during development of Eng-/-
mice [28]. Moreover, the pericyte-dependent permeability
in the retina of endoglin heterozygous mice (Eng?/-), a
model of HHT1, shows an increased leakiness and number
of permeability foci compared to wild type animals
(Fig. 8). In agreement with this finding, a recent article has
shown an increased permeability in endoglin-deficient EC
monolayers [62]. By contrast, a milder vascular phenotype
has been reported upon endoglin suppression in adult mice.
Thus, specific deletion of endoglin in 8- to 10-week-old
mice does not lead to markedly reduced mural cell cov-
erage, but to an altered localization within arteries and
veins [63]. These results suggest that the role of endoglin is
critical during de novo cell adhesion-dependent neoangio-
genesis, such as during development or inflammation.
However, once the initial endoglin-dependent adhesion
between ECs and SMCs has been established, other adhe-
sion and receptor molecules reinforce the ECs–SMCs
interaction and become the predominant adhesion forces
over the endoglin-integrin adhesion. Previous studies sup-
port the involvement of the interaction between endoglin
and integrins in vascular functions such as vasoconstrictor
or vasodilator responses where SMCs play a key role.
Thus, adult mice lacking SMC b1-integrin show a pro-
found loss of vasomotor control including the EC-
dependent vasodilation to acetylcholine and the VSMC-
dependent vasoconstriction to norepinephrine [59]. Also,
hypotensive and vasodilatory responses induced by
acetylcholine and bradykinin in Eng?/? animals were
markedly reduced in Eng?/-mice [64]. In addition, an
upregulation of cyclooxygenase-2 (COX-2) in the vascular
endothelium and increased urinary excretion of pros-
taglandin E2 in Eng?/- compared with Eng?/? mice has
been reported [48]. These results support the role of b1-
integrin and endoglin in vasomotor function.
SolEng, proteolytically cleaved from the membrane
form of endoglin, is present at high levels in a variety of
pathophysiological conditions including preeclampsia [21].
Although an anti-angiogenic activity for SolEng has been
reported [24, 34], its mechanism of action is poorly
understood. We found that SolEng can inhibit the adhesion
of VSMCs to ECs as well as induce podocytes detachment
in the kidney. Based on these results, we postulate that
SolEng binds integrins preventing not only adhesion of
vascular mural cells to ECs (competing with endothelial
membrane endoglin), but also the adhesion of podocytes to
the GBM (Fig. 10).This novel role for endoglin and SolEng
in cell adhesion during angiogenesis and vessel stabiliza-
tion involves the ZP domain via its binding to integrins, but
does not exclude an additional regulatory role of the orphan
domain, which can bind to TGF-b family members [24,
25]. The effect of SolEng in cell adhesion is supported by
the morphological changes observed in its presence
(Figs. 2c, 6a), which are likely due to the endoglin inter-
action with surface integrins. Furthermore, that SolEng
stably binds to the surface of VSMCs is clearly illustrated
after integrin activation with CXCL12 or MnCl2 (Fig. 6a;
Video #1 in Online Resource Supplemental material).
Noteworthy, SolEng induces vascular permeability and
hypertension in vivo [34, 35] and these effects are com-
patible with the antagonist role of SolEng on the interaction
between membrane bound endothelial endoglin and b1-
integrins present in mural cells or in podocytes. It should
be noted that because b1-integrins can interact with various
ECM proteins, interference of these activities by endoglin
may also contribute to the functional alterations observed.
Based on its modulatory action on vascular function, a
deleterious effect of soluble endoglin during in vivo
cFig. 6 Soluble endoglin binds to VSMCs and inhibits angiogenesis
in vivo. a Binding of soluble endoglin to VSMCs. Exponentially
growing UASMCs were incubated with a chimeric protein containing
the extracellular domain of endoglin fused to the Fc fragment of IgG
(Sol.Eng-Fc), and the integrins’ activators CXCL12 and MnCl2, as
indicated. After incubation with FITC-labeled anti-human IgG, cells
were fixed, counterstained with DAPI and analyzed by confocal
microscopy (lower panel). The fluorescence intensity was measured
using confocal microscopy (SP5, Leica) and represented as mean
values per cell. A representative experiment out of three made in
triplicate with similar results is shown. The statistical significance is
indicated (**p\ 0.005). b In vitro 7 days co-culture of bmMPC and
ECFC. bmMPC differentiate into VSMC/pericytes as evidenced by
the positivity for the antibodies specific for aSMA, PDGFRb, NG2,
Calponin I and Sm22a (green stain). A negative control antibody
(IgG) was also used. Endothelial cells (ECFC) are stained in red using
an antibody against von Willebrand factor. c–f Effect of soluble
endoglin on in vivo angiogenesis. c Nude mice (n = 3) were injected
with the coculture of bmMPC ? ECFC in matrigel either in the
absence (control) or in the presence of soluble endoglin (Sol.Eng;
5 lg/mL/plug). d After 1 week, plugs were extracted from the
animals. e Plug sections were stained with hematoxylin and eosin.
Arrowheads indicate the presence of vascular structures containing
erythrocytes. f Quantification of the vessels. The average of three
different experiments made in triplicate is shown (N nude mice = 9;
n = 9 plugs for each condition). The plugs treated with SolEng
display a lower number of vessels compared to controls (*p\ 0.04).
g Immunohistochemistry of plug sections. Arrowheads indicate the
staining of vascular endothelium with anti-CD31 antibodies and
mural cells with anti-aSMA. Staining of aSMA is almost absent in
plugs treated with soluble endoglin. A positive staining of arterioles
from the neighboring tissue is included as an internal control
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Fig. 7 Effect of silencing endoglin and b1 integrin in angiogenesis
assays in vivo. a Suppression of b1 integrin and endoglin using
specific siRNA was carried out in cultured bmMPC and ECFC,
respectively. Endothelial cells (ECFC) or smooth muscle cells
(bmMPC9) were stained with anti-CD105 (endoglin) in green or
anti-CD29 (b1 integrin) in red, respectively. b Quantification of the
vessels. The average of two different experiments performed in
triplicate is shown. The individual or combined suppression of
endoglin or b1 integrin in bmMPC or ECFC, respectively, leads to a
markedly reduced number of vessels compared to controls
(**p\ 0.01; ***p\ 0.005). c Four groups of nude mice (n = 3
each) were injected with the coculture of bmMPC ? ECFC in
matrigel either in the absence (scrambled siRNA; control) or in the
presence of siRNA-mediated suppression, as indicated. After 1 week,
plugs were extracted from the animals and stained with hematoxylin
and eosin. Arrowheads indicate the presence of vascular structures
containing erythrocytes























Fig. 8 Increased vascular permeability in Eng?/- mice. Eng?/- and
Eng?/? mice were perfused through the jugular vein with FITC-
dextran. After 2 h, animals were killed and eyes were removed and
dissected. Nineteen neuroretinas from ten different animals (six Eng?/
? and four Eng?/- mice) were isolated and mounted with antifade
solution. The green fluorescent labeling of the retinas was visualized
using a fluorescence microscope (Axiovert 200M, Zeiss). a Represen-
tative photographs from three Eng?/? and three Eng?/- mice, are
shown. An increased number of permeability foci and diffuse green
fluorescence background is observed in Eng?/- mice (arrows)
compared with Eng?/?. b Quantification of permeability spots
(**p = 0.01)
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embryogenesis, would be expected. Supporting this view,
SolEng? female mice crossed with non-transgenic males
led to a marked reduction in the weight of pups and the
number of pups per litter, respect to wild type mothers [35].
As a further proof of the major effect of SolEng on b1
integrin-mediated cell adhesion, we have assessed the
effect of high levels of SolEng on podocytes, present in
glomerular capillaries, which play a key role in regulating
glomerular protein filtration. It should be noted that
patients with preeclampsia present increased levels of
SolEng in plasma and proteinuria [34]. Moreover,
podocyturia is a diagnostic marker for preeclampsia
amongst high-risk pregnant patients [65], and generally
correlates with proteinuria [36, 37]. However, the mecha-
nism responsible for podocyturia in preeclampsia is
unknown. Thus, we hypothesized that SolEng could con-
tribute to podocyturia by detaching the glomerular
podocytes from capillaries. Experimental support for this
hypothesis was found using an animal model of transgenic
mice (Sol.Eng?), that mimics the high expression of
SolEng in preeclampsia [35]. The number of mural cells in
kidney non-glomerular blood vessels (small arterioles) was
similar between Sol.Eng? and wild type mice, whereas the
number of glomerular podocytes was greatly reduced in
Sol.Eng? compared to wild type mice. This finding is
reinforced by the presence podocytes and SolEng in the
urine of Sol.Eng?, but not of WT mice (Fig. 9; Online
Resource Supplemental Fig. 6D). These results suggest
that SolEng may lead to the detachment of podocytes from
GBM. Of note, podocytes are exposed to permanent tran-
scapillary filtration pressure and flow and must therefore
adhere tightly to the underlying GBM. The major cell–
matrix adhesion receptor in podocytes is the integrin a3b1,
which connects laminin a5b2c1 in the GBM through var-
ious adaptor proteins to the intracellular actin cytoskeleton.
Other cell–matrix adhesion receptors expressed by podo-
cytes include the integrins a2b1 and avb3 [19]. We have
previously shown that endoglin is a ligand for b1 integrins
[16]. Thus, we suggest that, in preeclampsia, SolEng that is
continuously being filtered through the glomerular capil-
laries reaching the Bowman’s capsule, can bind podocytes’
b1 integrins and facilitate their detachment from the GBM
(Fig. 10d, e). Accordingly, SolEng would play a key role in
podocyturia, a major characteristic of preeclampsia. Also,
our data provide a further indication that b1 integrins are
critical targets for membrane and SolEng.
Endoglin is a component of the TGF-b receptor complex
and TGF-b signaling regulates mural cell differentiation
and vessel maturation [10]. Thus, it is possible that the
endoglin-dependent functions analyzed here are also reg-
ulated by the TGF pathway. Indeed, in yolk sacs from
Eng?/- mice, TGF-b/ALK5/Smad2 signalling from ECs to
adjacent mesothelial cells is defective, leading to the fail-
ure of vSMCs to differentiate and associate with ECs so
that blood vessels are fragile and become dilated [54]. In
addition, inhibition of TGF-b signaling by systemic
expression of soluble endoglin in adult Eng?/? mice,
results in reduced levels of phospho-Smad2 in the retina,
decreased retinal function, impaired perfusion of the inner
retinal vasculature, loss of capillary integrity and break-
down of the blood–retinal barrier [66]. These results are in
agreement with our findings of membrane and soluble
endoglin and suggest a complex and redundant regulation
of vessel maturation.
In summary, we describe here a novel role of endoglin
and its soluble form (SolEng) in cellular adhesion involv-
ing mural cells/podocytes that may help to better
understand the function of endoglin in angiogenesis as well
cFig. 9 Analysis of podocytes in the kidney from Sol.Eng
? mice.
a Comparison between glomeruli of Sol.Eng? mice (n = 17) and
controls (n = 17). The overall structure of glomeruli in WT and
transgenic animals is similar, as evidenced by the hematoxylin and
eosin and trichromic staining, although a certain degree of leukocyte
infiltration was observed in Sol.Eng? mice. Immunostaining with
anti-aSMA, anti-podocin and anti-WT1 shows a positive signal in
podocytes from wild type animals and a reduced staining in the
Sol.Eng? glomeruli. Representative tissue sections are shown. b The
immunostaining of aSMA, podocin and WT1 shown in a was
quantified using the Image J software. Relative units (RU) of
podocyte staining from four different experiments are represented in
the vertical axis. c Thinprep on urine from Sol.Eng? mice (n = 5)
and controls (n = 5). Hematoxylin and eosin staining shows the
presence of cells in urine. Staining with anti-a-SMA, anti-podocin
and anti-WT1 indicates the presence of podocytes in the urine of
Sol.Eng? mice. d, g Protein levels of nephrin and podocalyxin were
measured in the urine of WT (n = 5) and Sol.Eng? (n = 5) mice
using an ELISA kit





































































































































Fig. 10 Schematic diagram showing the role of endoglin in integrin-
mediated cell adhesion between ECs and mural cells/podocytes. a–
c Blood vessels. a A normal blood vessel with an endothelial
monolayer facing the lumen surrounded by vascular mural cells
(VMCs) and ECM proteins. ECs and vascular mural cells share a
common basal membrane (BM). During vascular development and
stabilization, binding of the homeostatic chemokine CXCL12 to its
receptor CXCR4 leads to activation of b1-integrins in VMCs. Then,
endothelial endoglin binds to b1-integrins on VMCs. b In HHT1,
endoglin haploinsufficiency leads to a decreased binding of
endothelial endoglin to b1-integrins in VMCs. c In preeclampsia,
soluble endoglin competes with membrane bound endoglin for the
binding to b1-integrins in VMCs. d, e Kidney glomerulus. d A normal
glomerulus showing pericytes bound to the glomerular basal mem-
brane (GBM) through their surface integrins. e In preeclampsia,
soluble endoglin competes with GBM for the binding to surface
integrins in podocytes. The presence of endothelial endoglin in the
lumen of the vessel and the existence of other adhesion molecules
have been omitted for simplification
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as in several pathophysiological processes, such as
preeclampsia or HHT1.
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